US 9731023
Somatostatin receptor-based cancer therapy
granted A61KA61K35/28A61K38/179
Quick answer
US patent 9731023 (Somatostatin receptor-based cancer therapy) held by The Board of Regents of the University of Texas System expires Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Aug 15 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 28
- CPC classes
- A61K, A61K35/28, A61K38/179, A61K38/31, A61K47/46